Tajikistan
Tuberculosis profile
| High MDR-TB burden |
Population  2012 8 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB)        
Mortality (HIV+TB only)        
Prevalence  (includes HIV+TB)        
Incidence  (includes HIV+TB)        
Incidence (HIV+TB only)        
Case detection, all forms (%)        
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 2 041 (37) Relapse 327 (44)
Smear-negative 1 911 (35) Treatment after failure 146 (20)
Smear-unknown / not done 0 (0) Treatment after default 58 (8)
Extrapulmonary 1 532 (28) Other 217 (29)
Other 0 (0)      
Total new 5 484   Total retreatment 748  
           
Other (history unknown) 697        
Total new and relapse 5 811   Total cases notified 6 929  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.2 1.5 1.2
Age < 15 24 92 244
Laboratories 2012
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 1.9
Drug susceptibility testing (per 5 million population) 0.6
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 80   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 91  
Retreatment 71  
TB/HIV 2012 Number (%)
TB patients with known HIV status 6 375 (92)
HIV-positive TB patients 88 (1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 70 (80)
HIV-positive TB patients on antiretroviral therapy (ART) 78 (89)
HIV-positive people screened for TB 327  
HIV-positive people provided with IPT 157  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 13 (9.8–16) 56 (52–60)
MDR-TB cases among notified pulmonary
TB cases
490 (390–620) 420 (390–450)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 919 (45%) 496 (66%) 1 702
Laboratory-confirmed MDR-TB cases 286 278 694
Patients started on MDR-TB treatment     535
Financing TB control 2013
National TB programme budget (US$ millions) 46
% Funded domestically 10%
% Funded internationally 26%
% Unfunded 64%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data